[EQUITIES] Top drug makers to miss analysts Q2 expectations on growing R&D costs
Jul 18, 2016
[THE INVESTOR] South Korea’s major pharmaceutical companies are likely to post weaker-than-expected earnings for the second quarter of 2016, a local securities firm Shinhan Investment said on July 18.“Combined earnings of 10 major drug manufactures will stay around last year’s level at 115.8 billion won (US$119 million), missing the market expectation of 128 billion won,” Bae Ki-dal, an analyst at Shinhan Investment. 123rfThe analyst attributed the slow growth to declining technology exports and